Literature DB >> 14979715

Crystal structure of human prostaglandin F synthase (AKR1C3).

Junichi Komoto1, Taro Yamada, Kikuko Watanabe, Fusao Takusagawa.   

Abstract

Prostaglandin H(2) (PGH(2)) formed from arachidonic acid is an unstable intermediate and is efficiently converted into more stable arachidonate metabolites (PGD(2), PGE(2), and PGF(2)) by the action of three groups of enzymes. Prostaglandin F synthase (PGFS) was first purified from bovine lung and catalyzes the formation of 9 alpha,11 beta-PGF(2) from PGD(2) and PGF(2)(alpha) from PGH(2) in the presence of NADPH. Human PGFS is 3 alpha-hydroxysteroid dehydrogenase (3 alpha-HSD) type II and has PGFS activity and 3 alpha-HSD activity. Human lung PGFS has been crystallized with the cofactor NADP(+) and the substrate PGD(2), and with the cofactor NADPH and the inhibitor rutin. These complex structures have been determined at 1.69 A resolution. PGFS has an (alpha/beta)(8) barrel structure. The cofactor and substrate or inhibitor bind in a cavity at the C-terminal end of the barrel. The cofactor binds deeply in the cavity and has extensive interactions with PGFS through hydrogen bonds, whereas the substrate (PGD(2)) is located above the bound cofactor and has little interaction with PGFS. Despite being largely structurally different from PGD(2), rutin is located at the same site of PGD(2), and its catechol and rhamnose moieties are involved in hydrogen bonds with PGFS. The catalytic site of PGFS contains the conserved Y55 and H117 residues. The carbonyl O(11) of PGD(2) and the hydroxyl O(13) of rutin are involved in hydrogen bonds with Y55 and H117. The cyclopentane ring of PGD(2) and the phenyl ring of rutin face the re-side of the nicotinamide ring of the cofactor. On the basis of the catalytic geometry, a direct hydride transfer from NADPH to PGD(2) would be a reasonable catalytic mechanism. The hydride transfer is facilitated by protonation of carbonyl O(11) of PGD(2) from either H117 (at low pH) or Y55 (at high pH). Since the substrate binding cavity of PGFS is relatively large in comparison with those of AKR1C1 and AKR1C2, PGFS (AKR1C3) could catalyze the reduction and/or oxidation reactions of various compounds over a relatively wide pH range.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14979715     DOI: 10.1021/bi036046x

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  25 in total

Review 1.  Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis.

Authors:  William L Smith; Yoshihiro Urade; Per-Johan Jakobsson
Journal:  Chem Rev       Date:  2011-09-27       Impact factor: 60.622

2.  Characterization of disease-related 5beta-reductase (AKR1D1) mutations reveals their potential to cause bile acid deficiency.

Authors:  Jason E Drury; Rebekka Mindnich; Trevor M Penning
Journal:  J Biol Chem       Date:  2010-06-03       Impact factor: 5.157

3.  Multiple steps determine the overall rate of the reduction of 5alpha-dihydrotestosterone catalyzed by human type 3 3alpha-hydroxysteroid dehydrogenase: implications for the elimination of androgens.

Authors:  Yi Jin; Trevor M Penning
Journal:  Biochemistry       Date:  2006-10-31       Impact factor: 3.162

4.  Structures of prostaglandin F synthase from the protozoa Leishmania major and Trypanosoma cruzi with NADP.

Authors:  Spencer O Moen; James W Fairman; Steve R Barnes; Amy Sullivan; Stephen Nakazawa-Hewitt; Wesley C Van Voorhis; Bart L Staker; Donald D Lorimer; Peter J Myler; Thomas E Edwards
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2015-04-21       Impact factor: 1.056

5.  Structure of AKR1C3 with 3-phenoxybenzoic acid bound.

Authors:  Victoria J Jackson; Yuliana Yosaatmadja; Jack U Flanagan; Christopher J Squire
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2012-03-27

Review 6.  AKR1C3 as a target in castrate resistant prostate cancer.

Authors:  Adegoke O Adeniji; Mo Chen; Trevor M Penning
Journal:  J Steroid Biochem Mol Biol       Date:  2013-06-06       Impact factor: 4.292

Review 7.  Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights.

Authors:  Michael C Byrns; Yi Jin; Trevor M Penning
Journal:  J Steroid Biochem Mol Biol       Date:  2010-11-16       Impact factor: 4.292

8.  Prostaglandin and myokine involvement in the cyclooxygenase-inhibiting drug enhancement of skeletal muscle adaptations to resistance exercise in older adults.

Authors:  Todd A Trappe; Robert A Standley; Bozena Jemiolo; Chad C Carroll; Scott W Trappe
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-12-05       Impact factor: 3.619

9.  Human cytosolic hydroxysteroid dehydrogenases of the aldo-ketoreductase superfamily catalyze reduction of conjugated steroids: implications for phase I and phase II steroid hormone metabolism.

Authors:  Yi Jin; Ling Duan; Seon Hwa Lee; Helenius J Kloosterboer; Ian A Blair; Trevor M Penning
Journal:  J Biol Chem       Date:  2009-02-12       Impact factor: 5.157

10.  Crystal structure of human liver Delta4-3-ketosteroid 5beta-reductase (AKR1D1) and implications for substrate binding and catalysis.

Authors:  Luigi Di Costanzo; Jason E Drury; Trevor M Penning; David W Christianson
Journal:  J Biol Chem       Date:  2008-04-11       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.